Neurology
Found 614 results
2016
Zhang Y, Gauthier SA, Gupta A, Comunale J, Chiang GChia-Yi, Zhou D, Chen W, Giambrone AE, Zhu W, Wang Y.  2016.  Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM).. J Magn Reson Imaging. 44(2):426-32.
Zhang Y, Gauthier SA, Gupta A, Tu L, Comunale J, Chiang GC-Y, Chen W, Salustri CA, Zhu W, Wang Y.  2016.  Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection.. AJNR Am J Neuroradiol. 37(10):1794-1799.
Allen BB, Charles JA, Papadopoulos E, Avila EK.  2016.  Neurogenic orthostatic hypotension with critical illness neuropathy treated with droxidopa.. Auton Neurosci. 198:8-9.
Hodgson TS, Nielsen SM, Lesniak MS, Lukas RV.  2016.  Neurological Management of Von Hippel-Lindau Disease.. Neurologist. 21(5):73-8.
Schelke MW, Hackett K, Chen JL, Shih C, Shum J, Montgomery ME, Chiang GC, Berkowitz C, Seifan A, Krikorian R et al..  2016.  Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach.. Ann N Y Acad Sci. 1367(1):50-6.
Dayan M, Monohan E, Pandya S, Kuceyeski A, Nguyen TD, Raj A, Gauthier SA.  2016.  Profilometry: A new statistical framework for the characterization of white matter pathways, with application to multiple sclerosis.. Hum Brain Mapp. 37(3):989-1004.
Bourre B, Gueudry J, Lefaucheur R, Borden A, Maltête D, Patel SS, Van Tassel SHaseltine, Gupta MP, Orlin A, Nealon NM.  2016.  Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.. Neurology. 86(3):312-3.
Zhang Y, Gauthier SA, Gupta A, Chen W, Comunale J, Chiang GC-Y, Zhou D, Askin G, Zhu W, Pitt D et al..  2016.  Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation.. AJNR Am J Neuroradiol. 37(9):1629-35.
Merkler AE, Duggal I, Kaunzner U, Maciel CB, Miller AM, Scognamiglio T, Dinkin MJ.  2016.  Rapidly progressive bilateral optic nerve and retinal infarctions due to rhinocerebral mucormycosis and pseudoephedrine use.. Neurol Clin Pract. 6(6):549-552.
Murthy SB, Urday S, Beslow LA, Dawson J, Lees K, W Kimberly T, Iadecola C, Kamel H, Hanley DF, Sheth KN et al..  2016.  Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage.. J Neurol Neurosurg Psychiatry. 87(11):1169-1173.
Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D et al..  2016.  Relapses in multiple sclerosis: Relationship to disability.. Mult Scler Relat Disord. 6:10-20.
Noch EK.  2016.  Right Brain: Home is where the heart is.. Neurology. 87(24):e288-e289.
Navi BB, Parikh NS, Lerario MP, Merkler AE, Lappin RI, Fahimi J, Iadecola C, Kamel H.  2016.  Risk of Intracerebral Hemorrhage after Emergency Department Discharges for Hypertension.. J Stroke Cerebrovasc Dis. 25(7):1683-1687.
Lerario MP, Merkler AE, Gialdini G, Parikh NS, Navi BB, Kamel H.  2016.  Risk of Stroke After the International Classification of Diseases-Ninth Revision Discharge Code Diagnosis of Hypertensive Encephalopathy.. Stroke. 47(2):372-5.
Parikh NS, Cool J, Karas MG, Boehme AK, Kamel H.  2016.  Stroke Risk and Mortality in Patients With Ventricular Assist Devices.. Stroke. 47(11):2702-2706.
Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T, Perumal JS.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.
Baradaran H, Omran S, J Chazen L.  2016.  Teaching NeuroImages: Acute crossed cerebellar diaschisis.. Neurology. 86(14):e154-e155.
2015
Linden JR, Ma Y, Zhao B, Harris JMichael, Rumah KRashid, Schaeren-Wiemers N, Vartanian T.  2015.  Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination.. mBio. 6(3):e02513.
Babij R, Perumal JS.  2015.  Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.. Neuropsychiatr Dis Treat. 11:1221-9.
Perumal JS, Kister I, Howard J, Herbert J.  2015.  Disease exacerbation after rituximab induction in neuromyelitis optica.. Neurol Neuroimmunol Neuroinflamm. 2(1):e61.
Vargas WS, Monohan E, Pandya S, Raj A, Vartanian T, Nguyen TD, Rúa SMHurtado, Gauthier SA.  2015.  Measuring longitudinal myelin water fraction in new multiple sclerosis lesions.. Neuroimage Clin. 9:369-75.
Kuceyeski AF, Vargas W, Dayan M, Monohan E, Blackwell C, Raj A, Fujimoto K, Gauthier SA.  2015.  Modeling the relationship among gray matter atrophy, abnormalities in connecting white matter, and cognitive performance in early multiple sclerosis.. AJNR Am J Neuroradiol. 36(4):702-9.
Eskreis-Winkler S, Deh K, Gupta A, Liu T, Wisnieff C, Jin M, Gauthier SA, Wang Y, Spincemaille P.  2015.  Multiple sclerosis lesion geometry in quantitative susceptibility mapping (QSM) and phase imaging.. J Magn Reson Imaging. 42(1):224-9.
Rumah KRashid, Ma Y, Linden JR, Oo MLin, Anrather J, Schaeren-Wiemers N, Alonso MA, Fischetti VA, McClain MS, Vartanian T.  2015.  The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin.. PLoS Pathog. 11(5):e1004896.
Berti V, Murray J, Davies M, Spector N, Tsui WH, Li Y, Williams S, Pirraglia E, Vallabhajosula S, McHugh P et al..  2015.  Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals.. J Nutr Health Aging. 19(4):413-23.